Clinical trials: Nasopharyngeal Cancer, open to volunteers
Nasopharyngeal Carcinoma (NPC)
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
The purpose of this study was to evaluate the efficacy and safety of large fractionation radiotherapy in nasopharyngeal carcinoma patients, and to analyze whether Hypofractionated radiotherapy is not inferior to conventional…
- Trial name
- NCT06796270
- Testing
- Hypofractionated radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Nasopharyngeal Carcinoma
Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and…
- Trial name
- NCT05884983
- Testing
- participants will undergo dual-energy CT and endoscopy
- Where
- China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Nasopharyngeal Cancinoma (NPC)
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
Re-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life.
- Trial name
- NCT07528183
- Testing
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Carcinoma, Metastasis
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone.
- Conditions
- Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
- Trial name
- NCT04890522
- Testing
- Triprilimab(JS001), Cisplatin, 5-Fluorouracil
- Where
- China
- Volunteers
- 622 people
- Sponsor
- Sun Yat-sen University
Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma
Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma
This study focuses on a common side effect experienced by many patients after radiation therapy for nasopharyngeal cancer, which is a type of head and neck cancer.
- Conditions
- Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma, Radiotherapy Side Effects, Radiotherapy Side Effect
- Trial name
- NCT07189572
- Testing
- Triamcinolone Acetonide
- Volunteers
- 168 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nasopharyngeal Cancinoma (NPC)
Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma
This randomized trial evaluates a multimodal surveillance strategy in nasopharyngeal carcinoma patients with high-risk N3 cervical lymph node involvement after radiotherapy.
- Trial name
- NCT07692906
- Testing
- Multimodal Evaluation-Guided Surveillance Strategy
- Volunteers
- 80 people
- Sponsor
- Xuelei Ma MD
Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease, Recurrent Nasopharyngeal Carcinoma, Maximum Tolerated Dose
- Trial name
- AlloNK1 (NCT07247201)
- Testing
- Allogenic expanded Natural Killer Cells (AlloNK1)
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- Singapore General Hospital
Nasopharyngeal Carcinoma
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.
- Trial name
- NCT05514275
- Testing
- Endostatin and Capecitabine
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
- Trial name
- NCT07567742
- Testing
- Taurine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Swallowing-induced Pain
Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for…
- Trial name
- NCT06017895
- Testing
- doxepin solution
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients…
- Trial name
- NCT07311772
- Testing
- Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis
- Where
- 16 sites in China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC), EBV
KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment…
- Trial name
- NCT06752473
- Testing
- KSD-101
- Volunteers
- 10 people
- Sponsor
- Kousai Bio Co., Ltd.
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk…
- Trial name
- NCT07540390
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and…
- Trial name
- NCT07412314
- Testing
- Proton therapy, Proton radiation therapy
- Where
- 2 sites in China
- Volunteers
- 52 people
- Sponsor
- Guangzhou Concord Cancer Center
Nasopharyngeal Carcinoma by AJCC V9 Stage
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT07268690
- Testing
- Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT07101744
- Testing
- Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University